This study looked at the benefit of oral CFA on knee range of motion and function in patients with OA.
Dietary fatty acid composition is important for the prevention of chronic disease. Recent studies have suggested that myriostoleic acid (one of the CFA in Celadrin) may act by inhibition of 5-lipoxygenase, a potent mediator in the inflammatory process

64 patients with chronic knee OA were evaluated at baseline and at 30 and 68 days after consuming either placebo (vegetable oil; n=31) or CFA capsules (Celadrin; n=33). Subjects and investigators were blinded to the treatment assignment. Amber coloured soft gel capsules identical in shape and size were used to blind study participants.

Participants were asked to consume 6 capsules per day with makeup days allowed for missed dosages. Patients were asked to consume 3 capsules in the morning and 3 in the evening.

Clinical evaluation at 30 and 68 days included physician assessment for pain, stiffness and discomfort, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI).

After 68 days, patients treated with CFA exhibited significant increase in knee flexion compared to patients given the placebo. Neither group reported improvement in knee extension. In the CFA group 58% of patients experienced a reduction in pain compared to 32% of patients given placebo. Neither group exhibited changes in morning stiffness. Patient responses to the LAI indicated a significant shift towards functional improvement for the CFA group in all four response categories after 68 days. This was not observed in the placebo group.

Therefore, compared to the placebo group, CFA provides an improvement in knee range of motion and overall function in patients with OA of the knee. CFA may be an alternative to the use of nonsteroidal anti-inflammatory drugs for the treatment of OA.

Arthritis Information
Clinical Research
Distributors Wanted